Mealey's PI/Product Liability - FDCA Violations Can't Support False Claims In Trasylol Suit, Judge Says

Mealey's PI/Product Liability - FDCA Violations Can't Support False Claims In Trasylol Suit, Judge Says

NEWARK, N.J. - A whistle-blower cannot argue that Bayer Corp. violated the False Claims Act (FCA) by misbranding the drug Trasylol in violation of the Food, Drug and Cosmetic Act (FDCA), a New Jersey federal judge ruled April 11 in dismissing the complaint without prejudice for most claims (United States of America, et al., ex rel. Laurie Simpson v. Bayer Corp., et al., No. 05-3895, D. N.J.).

Find full version on lexis Advance®
Access this news story on lexis.com®